Literature DB >> 8214298

Surgical management of squamous cell carcinoma of the base of the tongue.

D H Kraus1, A P Vastola, A G Huvos, R H Spiro.   

Abstract

An 11-year experience with 100 patients who had surgery as definitive treatment for squamous cell carcinoma of the base of the tongue between 1979 and 1989 has been retrospectively reviewed. Although 81% of the patients had stage III or stage IV disease, mandible continuity was maintained in 86%, and the larynx was preserved in 80%. Lymphadenectomy was performed in conjunction with the primary resection in a total of 89 patients, including 62 patients who had clinically evident metastases. Postoperative radiation was administered to 63 patients because of positive resection margins (17), positive cervical lymph nodes (34), or high tumor stage (12). Overall and disease-specific 5-year survival rates for the entire group were 55% and 65%, respectively. The 5-year disease-specific survival rates for stages I/II, III, and IV were 77%, 64%, and 59%, respectively. Local control was achieved in all but 18 patients. Our results indicate that surgery remains a viable treatment option for patients with advanced base-of-tongue cancer. Prospective trials are necessary to compare surgery versus definitive radiotherapy with respect to patients' survival and quality of life.

Entities:  

Mesh:

Year:  1993        PMID: 8214298     DOI: 10.1016/s0002-9610(05)80338-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Oncologic and functional results after transoral laser microsurgery of tongue base carcinoma.

Authors:  Martin Canis; Friedrich Ihler; Hendrik A Wolff; Hans Christiansen; Christoph Matthias; Wolfgang Steiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-05       Impact factor: 2.503

Review 2.  Controversies in the management of tongue base cancer.

Authors:  J P O'Neill; J P Hughes; K P Manning; J E Fenton
Journal:  Ir J Med Sci       Date:  2008-09-23       Impact factor: 1.568

3.  Treatment of base of tongue cancer, stage III and stage IV with primary surgery: survival and functional outcomes.

Authors:  Khaled Al-Qahtani; Jen Rieger; Jeffery R Harris; Alex Mlynarek; David Williams; Tahera Islam; Hadi Seikaly
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-25       Impact factor: 2.503

4.  Oral tongue cancer patients show a better overall survival than base of tongue cancer patients.

Authors:  Liuyang Zhang; Xuan Zhou; Xiaofeng Yao; Yansheng Wu; Qiang Zhang; Lun Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-03       Impact factor: 4.553

5.  Long-term follow-up and a detailed prognostic analysis of patients with oropharyngeal cancer treated with radiotherapy.

Authors:  Natsuo Tomita; Takeshi Kodaira; Kazuhisa Furutani; Hiroyuki Tachibana; Yasuhisa Hasegawa; Akihiro Terada; Kenji Hanai; Taijirou Ozawa; Tatsuya Nakamura; Nobukazu Fuwa
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-27       Impact factor: 4.553

6.  Relationship Between p16 Expression and Prognosis in Patients with Oropharyngeal Cancer Undergoing Surgery.

Authors:  Kota Kida; Tomonori Terada; Nobuhiro Uwa; Yoshihiko Omori; Takashi Fujii; Yasuhiko Tomita; Kenzo Tsuzuki; Hiroki Nishikawa; Masafumi Sakagami
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

7.  Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience.

Authors:  Leechuan Andy Chen; Christopher J Anker; Jason P Hunt; Luke O Buchmann; Kenneth F Grossmann; Kenneth Boucher; Li-Ming Christine Fang; Dennis C Shrieve; Ying J Hitchcock
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

8.  Primary surgery versus chemoradiotherapy for advanced oropharyngeal cancers: a longitudinal population study.

Authors:  Daniel O'Connell; Hadi Seikaly; Russell Murphy; Charles Fung; Tim Cooper; Aaron Knox; Rufus Scrimger; Jeffrey R Harris
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-04-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.